The executive line-up at soon-to-be number one generics company Sandoz – People on the move
the pharmaceutical sector, including the executive line-up at
soon-to-be number one generics company Sandoz.
At Novartis' generics subsidiary Sandoz, Dr Andreas Strüngmann will be responsible for the regional operations in Europe, Africa and Asia-Pacific as the company carries out a restructuring and the integration of soon-to-be-acquired Hexal and Eon Labs. Meanwhile, Dr Thomas Strüngmann will continue in the position of head of regional operations in Germany, the Americas and Middle East. Both will join the Sandoz Executive Committee.
Other members of Sandoz executive committee will include Kevin Plummer as chief financial officer, Dr Gerhard Schaefer as head of product development and Markus Delfosse as head of technical operations. The anti-infectives business unit will be headed by Ernst Meijnders and biopharmaceuticals by Dr Patrick Vink. Dr Bernhard Hampl, currently CEO of Eon Labs, has been designated as new head of the US operations of Sandoz and will report to Thomas Strüngmann.
William Sullivan has been appointed the new chief executive at Agilent, replacing Ned Barnholt who is retiring. Meanwhile, Adrian Dillon has been appointed executive vice president, finance and administration, effective 1 March.
Jon Tomson has joined the International Society of Pharmaceutical Engineering's technical advisory team and will act as the ISPE's liaison to major universities in support of the Pharmaceutical Manufacturing Professional of the Future initiative.
Fluid handling specialist Swagelok has named Ken Malec to the position of vice president, continuous improvement, responsible for developing manufacturing and in-bound supply chain strategies.
Anti-counterfeiting technology specialist Robin Koh of the Massachusetts Institute of Technology has joined SupplyScape as chief strategy officer. While at MIT, Koh led the university's work with the US Food and Drug Administration (FDA), developing methods for fighting counterfeit drugs.
Spectrum Chemical and Laboratory Products has appointed Paul McMinn as its new director of laboratory sales. He previously held positions at Commerce One and Fisher Scientific.
UK drug delivery firm BioProgress has appointed two new non-executive directors, namely Tony Fabrizi, the founding director of finance firm Ghaliston and Richard Trevillion, the founder and CEO of Amity Partners, a healthcare finance business. Graham Cole has resigned as a non-executive director.
